Jove
Visualize
Contact Us

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent SWI/SNF Deficiency Defines a Subset of Peripheral T-Cell Lymphoma With Distinct Clinicopathologic Features.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Gα<sub>s</sub> variant detection discerns skeletal cell types involved in fibrous dysplasia pathogenesis.

Bone·2026
Same author

Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report.

Journal of medical case reports·2021
Same author

Integrating neurophysiologic relevance feedback in intent modeling for information retrieval.

Journal of the Association for Information Science and Technology·2019
Same author

Enhancing hemotherapy safety through pertinent diagnostic testing and electronic "provisional diagnosis" reporting: expanding roles for blood bank technologists in biovigilance and patient safety.

Transfusion·2018
Same author

Expression of CD30 as a biomarker to predict response to brentuximab vedotin.

Histopathology·2015
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

ADAMTS13 activity and inhibitor.

Adriana Doldan-Silvero1, Carlos Acevedo-Gadea, Clandine Habib

  • 1Department of Pathology, Baystate Medical Center/Western Campus of Tufts University School of Medicine, Springfield, Massachusetts, USA.

American Journal of Hematology
|August 30, 2008
PubMed
Summary

Thrombotic thrombocytopenic purpura (TTP) is linked to ADAMTS13 deficiency. While low enzyme activity (<10%) aids diagnosis and predicts relapse, it is not recommended as an initial TTP test.

More Related Videos

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

Related Experiment Videos

Last Updated: Jul 2, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

Area of Science:

  • Hematology
  • Clinical Biochemistry

Background:

  • Thrombotic thrombocytopenic purpura (TTP) is frequently associated with acquired or congenital deficiency of ADAMTS13, a metalloprotease that cleaves von Willebrand factor.
  • Severe ADAMTS13 deficiency (<10% activity) is diagnostic of TTP in appropriate clinical contexts and is linked to a higher risk of relapse.

Purpose of the Study:

  • To evaluate the diagnostic utility and prognostic value of ADAMTS13 testing in patients with TTP.
  • To investigate the short-term prognostic usefulness of ADAMTS13 testing during acute TTP episodes.

Main Methods:

  • Review of prospective and retrospective studies on TTP patients.
  • Analysis of ADAMTS13 enzyme activity levels in relation to diagnosis and clinical outcomes.

Main Results:

  • Undetectable ADAMTS13 activity (<10%) is specific for TTP but not present in all diagnosed patients, thus not recommended for initial diagnosis.
  • Severe protease deficiency is associated with an increased likelihood of TTP relapse, indicating its value as a recurrence indicator.

Conclusions:

  • ADAMTS13 testing is valuable for diagnosing TTP in specific clinical settings and predicting relapse.
  • Further prospective studies are needed to fully establish the short-term prognostic utility of ADAMTS13 testing during acute TTP.